- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.04. | Organon acquires Actemra biosimilar's US rights from Biogen | ||
| 02.04. | RFK Jr swings axe at US health agencies | ||
| 02.04. | AIRNA secures $155m to bring RNA-candidate to clinic | ||
| 02.04. | Amneal and Shilpa introduce Boruzu in US for cancer treatment | ||
| 02.04. | FDA accepts priority review of Apellis' Empaveli sNDA for kidney diseases | ||
| 01.04. | Magazine: Are European biopharma manufacturers 'nearshoring'? | ||
| 01.04. | CNS market resurgence: a decade-long slump ends with $80bn milestone | ||
| 01.04. | Judge rejects J&J's $9bn talc settlement for third time | ||
| 01.04. | Reshoring efforts in US FMCG business begins, but cost increases are likely | ||
| 01.04. | Platform trials: The challenges, benefits, and best practices to maximize results with an EDC platform | ||
| 01.04. | BioVersys secures patent claims in China for BV100 | ||
| 01.04. | FDA approves Bavarian Nordic's freeze-dried mpox and smallpox vaccine | ||
| 01.04. | How will AI shape the future of the NHS? | ||
| 01.04. | Large pharma drug licensing from China hits high at 28% in 2024 | ||
| 01.04. | Pfizer's RSV vaccine wins expanded approval in EU, gaining edge over GSK | ||
| 01.04. | NHS England abolished: a bold cure or a risky operation? | ||
| 01.04. | Apollomics and LaunXP agree on NSCLC treatment in Asia | ||
| 01.04. | FDA approves AstraZeneca's Imfinzi combo for bladder cancer | ||
| 01.04. | Pharmaceutical Technology Excellence Awards 2025: NorthWest EHealth | ||
| 01.04. | ACC 2025: Imbria's ninerafaxstat data shows potential for cardiometabolic HFpEF | ||
| 31.03. | Cell and gene therapy collections: The need for consistency | ||
| 31.03. | Sanofi's Qfitlia approved by FDA as first haemophilia therapy for all patients | ||
| 31.03. | Biopharma IPOs showed signs of recovery in 2024 | ||
| 31.03. | Vertex halts development of diabetes cell therapy after trial failure | ||
| 31.03. | Saving shelved ultra-rare therapies through unorthodox funding |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
